Establishment Labs Holdings Inc. (NASDAQ:ESTA) CEO Quiros Juan Jose Chacon Sells 3,866 Shares

Establishment Labs Holdings Inc. (NASDAQ:ESTA) CEO Quiros Juan Jose Chacon sold 3,866 shares of the company’s stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $45.01, for a total transaction of $174,008.66. Following the transaction, the chief executive officer now owns 215,030 shares in the company, valued at approximately $9,678,500.30. The sale was disclosed in a filing with the SEC, which is available at this link.

Quiros Juan Jose Chacon also recently made the following trade(s):

• On Monday, July 1st, Quiros Juan Jose Chacon sold 6,839 shares of Establishment Labs stock. The shares were sold at an average price of $45.30, for a total value of $309,806.70.

Establishment Labs Price Performance

Establishment Labs stock traded down $0.98 during trading on Wednesday, reaching $43.31. The company had a trading volume of 140,282 shares, compared to its average volume of 378,680. The firm has a market capitalization of $1.19 billion, a PE ratio of -14.11 and a beta of 1.24. The firm’s 50-day simple moving average is $49.51 and its 200 day simple moving average is $44.56. The company has a debt-to-equity ratio of 3.38, a quick ratio of 2.73 and a current ratio of 4.24. Establishment Labs Holdings Inc. has a 1-year low of $16.96 and a 1-year high of $73.00.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.58) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.07. Establishment Labs had a negative net margin of 53.12% and a negative return on equity of 206.05%. The firm had revenue of $37.17 million for the quarter, compared to analyst estimates of $35.61 million. During the same period last year, the company posted ($0.48) EPS. Establishment Labs’s quarterly revenue was down 20.1% compared to the same quarter last year. As a group, equities research analysts anticipate that Establishment Labs Holdings Inc. will post -1.79 earnings per share for the current fiscal year.

Institutional Trading of Establishment Labs

A number of institutional investors have recently made changes to their positions in ESTA. FNY Investment Advisers LLC purchased a new position in Establishment Labs in the 4th quarter valued at $93,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Establishment Labs by 67.2% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,591 shares of the company’s stock worth $119,000 after purchasing an additional 1,845 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Establishment Labs during the 4th quarter worth approximately $120,000. Legato Capital Management LLC grew its position in shares of Establishment Labs by 63.1% in the fourth quarter. Legato Capital Management LLC now owns 8,438 shares of the company’s stock valued at $218,000 after purchasing an additional 3,263 shares in the last quarter. Finally, Concurrent Investment Advisors LLC acquired a new stake in shares of Establishment Labs in the first quarter valued at approximately $263,000. 72.91% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on ESTA shares. Citigroup lowered Establishment Labs from a “buy” rating to a “neutral” rating and set a $60.00 price objective on the stock. in a report on Wednesday, May 22nd. Mizuho lifted their price objective on shares of Establishment Labs from $65.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, June 6th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $56.00.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.